Maternal serum laeverin (aminopeptidase Q) measured in the first trimester of pregnancy does not predict preeclampsia

Abstract

<i>Objective</i>: The aim of this study was to compare the laeverin level in maternal serum from first trimester (11–14 weeks) of pregnancy between normal pregnancies and pregnancies that later developed preeclampsia (PE).<p><p>

<i>Material and methods</i>: This was a case-cohort study. The laeverin concentration was measured in cases with preterm PE (<i>n</i> = 55), term PE (<i>n</i> = 95), and a reference group of randomly selected women with normal pregnancy outcome (<i>n</i> = 200) in stored serum samples collected from the double-test as part of the combined first trimester trisomy 21 screening program. The samples were thawed and analyzed for laeverin. The median gestational age at blood sampling was 77 days (range 57–96 days). Multiple regression analysis was performed to establish a normal median. Concentrations were converted to multiples of the median (MoM) and groups were compared using the Mann–Whitney U-test.<p><p>

<i>Results</i>: In the reference group, laeverin was significantly correlated with gestational age (<i>r</i> = 0.18, <i>p</i> = .01) and its concentration ranged from 41–393 µg/L. No significant differences in the median laeverin MoM were found between the reference group (1.01 MoM) and cases with preterm PE (0.98 MoM) or term PE (0.96 MoM).<p><p>

<i>Conclusions</i>: First trimester maternal serum laeverin level cannot be used to predict preeclampsia.